<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2849">
  <stage>Registered</stage>
  <submitdate>6/07/2010</submitdate>
  <approvaldate>6/07/2010</approvaldate>
  <nctid>NCT01170065</nctid>
  <trial_identification>
    <studytitle>Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)</studytitle>
    <scientifictitle>A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-013788-21</secondaryid>
    <secondaryid>1199.35</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BIBF 1120
Treatment: drugs - BIBF 1120
Treatment: drugs - BIBF 1120
Treatment: drugs - BIBF 1120

Experimental: BIBF 1120 low qd - Low dose BIBF 1120 once daily

Experimental: BIBF 1120 low bid - Low dose BIBF 1120 twice daily

Experimental: BIBF 1120 medium bid - Intermediate dose BIBF 1120 twice daily

Experimental: BIBF 1120 high bid - High dose BIBF 1120 twice daily


Treatment: drugs: BIBF 1120
Intermediate dose BIBF 1120 twice daily

Treatment: drugs: BIBF 1120
High dose BIBF 1120 twice daily

Treatment: drugs: BIBF 1120
Low dose BIBF 1120 twice daily

Treatment: drugs: BIBF 1120
Low dose BIBF 1120 once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Forced vital capacity decline</outcome>
      <timepoint>3 years average</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>3 years average</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>3 years average</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Diffusing capacity of the lung for carbon monoxide (DLco) decrease</outcome>
      <timepoint>3 years average</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Idiopathic Pulmonary Fibrosis (IPF) acute exacerbation</outcome>
      <timepoint>3 years average</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical examination</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Adverse Events (AEs), frequency of serious AE and AE that may lead to drug discontinuation</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first Idiopathic Pulmonary Fibrosis (IPF) acute exacerbation</outcome>
      <timepoint>up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signs (BP, PR)</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weight</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically significant changes in liver transaminases (AST,ALT)</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically significant changes in gamma-GT</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically significant changes in alkaline phosphatase (PA)</outcome>
      <timepoint>at 1year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>absolute and relative change from baseline in FVC values (mL and % predicted)</outcome>
      <timepoint>3 years average</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically significant changes in total bilirubin</outcome>
      <timepoint>at 1 year, 2 years, 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Patient with a primary diagnosis of IPF (according to the 2000 American Thoracic
             Society/European Respiratory Society (ATS/ERS) criteria, who are willing to continue
             trial medication.

          2. Written informed consent signed prior to entry into the study, in accordance with
             International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local
             law

          3. Completion of 1199.30 study and still under treatment (i.e. not discontinued in parent
             trial)</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Any disease that may put the patient at risk when participating in this trial.
             Reconsider carefully all exclusion criteria of trial 1199.30. However, patients may
             qualify for participation even though exclusion criteria may have been met during the
             course of participation in 1199.30, if the investigator's benefit-risk assessment
             remains favourable.

          2. Participation in another experimental clinical trial (except 1199.30) in the last 8
             weeks.

          3. Women who are breast feeding or of child bearing potential not using a highly
             effective method of birth control for at least one month prior to inclusion and at
             least 10 weeks after end of active therapy.

             Highly effective methods of birth control are defined as those which result in a low
             failure rate (i.e. less than 1 % per year) when used consistently and correctly, such
             as implants, injectables, combined oral contraceptives, some Intra Uterine Devices
             (IUDs), sexual abstinence or vasectomized partner. Female patients will be considered
             of childbearing potential unless surgically sterilized by hysterectomy or bilateral
             tubal ligation, or post-menopausal for at least two years.

          4. Sexually active males not committing to using condoms during the course of the study
             and at least 10 weeks after the end of active therapy (except if their partner is not
             of childbearing potential).

          5. Patients who require full-dose anticoagulation (e.g. vitamin K antagonists, heparin,
             hirudin etc).

          6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel
             etc) therapy.

          7. Known or suspected active alcohol or drug abuse.

          8. Patient not compliant in previous trial, with trial medication or trial visits.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>198</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>Boehringer Ingelheim Investigational Site - Glen Osmond</hospital>
    <hospital>Boehringer Ingelheim Investigational Site - Woodville</hospital>
    <hospital>Boehringer Ingelheim Investigational Site - Perth</hospital>
    <postcode> - Glen Osmond</postcode>
    <postcode> - Woodville</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanjing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>DIJON Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 18</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Donaustauf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg/Breisgau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Großhansdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Alexandroupolis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Deszk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ascoli Piceno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Terni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Trieste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Westbury on Trym</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with
      Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.

      The primary objective will be to establish the long term tolerability and safety profile of
      BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF).

      As a secondary objective the effects of long term treatment with BIBF 1120 on survival as
      well as safety and efficacy parameters will be investigated in an open-label, not randomized,
      un-controlled design.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01170065</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>